Macrofollicular Variant of Follicular Thyroid Carcinoma (MV-FTC) with a Somatic DICER1 Gene Mutation: Case Report and Review of the Literature.


Journal

Head and neck pathology
ISSN: 1936-0568
Titre abrégé: Head Neck Pathol
Pays: United States
ID NLM: 101304010

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 08 06 2020
accepted: 17 07 2020
revised: 03 07 2020
pubmed: 28 7 2020
medline: 15 12 2021
entrez: 27 7 2020
Statut: ppublish

Résumé

Benign thyroid lesions such as multinodular goiter and adenomatoid nodules are well-circumscribed lesions displaying a macrofollicular growth pattern and lack of nuclear atypia. The highly unusual macrofollicular variant of follicular thyroid carcinoma (MV-FTC) mirrors these attributes and is thereby misclassified by cytological examination of fine-needle aspiration biopsies. The MV-FTC diagnosis is instead suggested following histological investigation, in which malignant attributes, most commonly capsular invasion, are noted. The bulk of MV-FTCs described in the literature arise in younger female patients and carry an excellent prognosis. A recent coupling to mutations in the DICER1 tumor suppressor gene has been proposed, possibly indicating aberrancies in micro-RNA (miRNA) patterns as responsible of the tumorigenic process. We describe the cytological, histological and molecular phenotype of a 35 mm large MV-FTC arising in the right thyroid lobe of a 33-year-old female with a family history of multinodular goiter. The tumor was encapsulated and strikingly inconspicuous in terms of cellularity and atypia, but nevertheless displayed multiple foci with capsular invasion. A next-generation molecular screening of tumor DNA revealed missense variants in DICER1 (p. D1709N) and MET (p. T1010I), but no established fusion gene events. After sequencing of germline DNA, the DICER1 mutation was confirmed as somatic, while the MET variant was constitutional. The patient is alive and well, currently awaiting radioiodine treatment. This MV-FTC mirrors previous publications, suggesting that these tumors carry a favorable prognosis and predominantly arise in younger females. Moreover, DICER1 mutations should be considered a common driver event in the development of MV-FTCs.

Identifiants

pubmed: 32712880
doi: 10.1007/s12105-020-01208-1
pii: 10.1007/s12105-020-01208-1
pmc: PMC8134796
doi:

Substances chimiques

DICER1 protein, human EC 3.1.26.3
Ribonuclease III EC 3.1.26.3
DEAD-box RNA Helicases EC 3.6.4.13

Types de publication

Case Reports Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

668-675

Subventions

Organisme : Cancerfonden
ID : Junior Clinical Investigator Award

Références

Oncotarget. 2019 Mar 5;10(19):1785-1797
pubmed: 30956758
J Clin Endocrinol Metab. 2018 May 1;103(5):2009-2015
pubmed: 29474644
F1000Res. 2015 Jul 10;4:214
pubmed: 26925222
Science. 2009 Aug 21;325(5943):965
pubmed: 19556464
Endocr J. 2008 Oct;55(5):889-94
pubmed: 18552462
J Clin Endocrinol Metab. 2018 Jul 1;103(7):2640-2650
pubmed: 29726952
N Engl J Med. 2012 Jan 19;366(3):234-42
pubmed: 22187960
Thyroid. 2020 Jan;30(1):72-80
pubmed: 31701808
Oncotarget. 2015 Feb 20;6(5):2604-14
pubmed: 25605252
Endocrinology. 2015 Apr;156(4):1590-601
pubmed: 25594698
Clin Cancer Res. 2018 Jul 1;24(13):3059-3068
pubmed: 29615459
Hum Mutat. 2011 Dec;32(12):1381-4
pubmed: 21882293
Mol Cell Endocrinol. 2017 Nov 15;456:44-50
pubmed: 28011236
J Med Genet. 2011 Apr;48(4):273-8
pubmed: 21266384
Eur J Cancer. 2019 Feb;108:41-49
pubmed: 30648628
Arch Pathol Lab Med. 2019 Nov;143(11):1364-1372
pubmed: 31100017
Mod Pathol. 2020 Jul;33(7):1264-1274
pubmed: 31937902
Oncogene. 2014 Nov 6;33(45):5295-302
pubmed: 24909177
PLoS One. 2013 Sep 02;8(9):e71969
pubmed: 24023722
Neoplasia. 2015 Aug;17(8):650-60
pubmed: 26408257
Cancer Res. 2003 Oct 1;63(19):6272-81
pubmed: 14559814
Hum Mutat. 2019 Nov;40(11):1939-1953
pubmed: 31342592
Endocr Pathol. 2013 Sep;24(3):167-8
pubmed: 23564026
J Clin Endocrinol Metab. 2013 Sep;98(9):E1562-6
pubmed: 23833040
Thyroid Res. 2020 Jun 13;13:10
pubmed: 32547644
Cancers (Basel). 2019 Sep 26;11(10):
pubmed: 31561592
Thyroid. 2017 Nov;27(11):1341-1346
pubmed: 29091573
Ann Diagn Pathol. 2009 Apr;13(2):101-5
pubmed: 19302958
Virchows Arch. 2018 Nov;473(5):639-643
pubmed: 29860621
Cancer Res. 2014 May 15;74(10):2742-9
pubmed: 24675358
Am J Surg Pathol. 2005 Apr;29(4):544-9
pubmed: 15767811
Endocr Relat Cancer. 2020 May;27(5):295-308
pubmed: 32163919

Auteurs

L Samuel Hellgren (LS)

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Department of Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden.

Martin Hysek (M)

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Department of Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden.

Kenbugul Jatta (K)

Department of Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden.

Jan Zedenius (J)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Department of Breast, Endocrine Tumors and Sarcoma, Karolinska University Hospital, Stockholm, Sweden.

C Christofer Juhlin (CC)

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. christofer.juhlin@ki.se.
Department of Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden. christofer.juhlin@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH